Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Common Equity data on record, last reported at -$98.0 million in Q4 2025.

  • For Q4 2025, Common Equity rose 70.92% year-over-year to -$98.0 million; the TTM value through Dec 2025 reached -$98.0 million, up 70.92%, while the annual FY2025 figure was -$98.0 million, 70.92% up from the prior year.
  • Common Equity reached -$98.0 million in Q4 2025 per INDV's latest filing, up from -$257.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $121.0 million in Q4 2021 and bottomed at -$337.0 million in Q4 2024.
  • Average Common Equity over 5 years is -$180.7 million, with a median of -$220.5 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 1126.67% in 2023, then surged 70.92% in 2025.
  • A 5-year view of Common Equity shows it stood at $121.0 million in 2021, then crashed by 112.4% to -$15.0 million in 2022, then plummeted by 1126.67% to -$184.0 million in 2023, then crashed by 83.15% to -$337.0 million in 2024, then soared by 70.92% to -$98.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$98.0 million in Q4 2025, -$257.0 million in Q2 2025, and -$285.0 million in Q1 2025.